Ardelyx/$ARDX
1D1W1MYTD1Y5YMAX
Capital at risk
About Ardelyx
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
- Ticker
- $ARDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 489
- Headquarters
- Waltham, United States
- Website
- www.ardelyx.com
Ardelyx Metrics
BasicAdvanced
$842M
-
-$0.23
0.69
-
Price and volume
Market cap
$842M
Beta
0.69
52-week high
$8.40
52-week low
$3.31
Average daily volume
4.1M
Financial strength
Current ratio
3.342
Quick ratio
2.891
Long term debt to equity
1.885
Total debt to equity
1.896
Interest coverage (TTM)
-1.24%
Profitability
EBITDA (TTM)
-32.106
Gross margin (TTM)
75.02%
Net profit margin (TTM)
-12.35%
Operating margin (TTM)
-7.86%
Effective tax rate (TTM)
-0.41%
Revenue per employee (TTM)
$920,000
Management effectiveness
Return on assets (TTM)
-4.25%
Return on equity (TTM)
-38.61%
Valuation
Price to revenue (TTM)
1.836
Price to book
5.65
Price to tangible book (TTM)
5.65
Price to free cash flow (TTM)
-46.191
Free cash flow yield (TTM)
-2.16%
Free cash flow per share (TTM)
-0.073
Growth
Revenue change (TTM)
16.77%
Earnings per share change (TTM)
-4.00%
3-year revenue growth (CAGR)
75.89%
3-year earnings per share growth (CAGR)
-7.52%
10-year earnings per share growth (CAGR)
-22.48%
What the Analysts think about Ardelyx
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Analyst projections of the future price of Ardelyx stock.
Bulls say / Bears say
Combined product revenue reached a quarterly record of $118.1 million in Q2 2026, up 31% year on year. That shows Ardelyx is building a sizeable commercial business rather than relying solely on future clinical prospects. (BioSpace)
IBSRELA is in a Phase 3 trial for chronic idiopathic constipation, with enrolment expected to finish by the end of 2026 and results due in the second half of 2027. A positive result could expand the drug’s addressable patient population beyond IBS-C. (BioSpace)
Management expects Ardelyx to reach sustained profitability in 2027 and has lowered its 2026 operating-expense outlook to below $500 million. If revenue growth continues, this could turn the company’s expanding sales base into earnings. (The Motley Fool)
More stringent prior authorisations and step edits slowed new IBSRELA patient starts, prompting Ardelyx to cut its 2026 sales forecast to $350–$370 million from $410–$430 million. The company has also said the timing of its $1 billion long-term sales goal is under review. (BioSpace)
A federal appeals court upheld the decision to keep oral phosphate-lowering drugs in Medicare’s dialysis payment bundle, and Ardelyx said it would not pursue further litigation. The company withdrew XPHOZAH’s long-term sales guidance, leaving its future growth potential less certain. (BioSpace)
Despite record quarterly product revenue, Ardelyx reported a $16.7 million net loss in Q2, while research and selling expenses rose from a year earlier. Its 2027 profitability goal therefore depends on revenue growth outpacing a substantial cost base. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
Ardelyx Financial Performance
Revenues and expenses
Ardelyx Earnings Performance
Company profitability
Upcoming events
No upcoming events
Ardelyx News
AllArticlesVideos
Kaplan Fox Reminds Ardelyx, Inc. (ARDX) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 16, 2026
Newsfile Corp17 hours ago
ARDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
Newsfile Corp1 day ago
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX)
Newsfile Corp1 day ago
Funds containing Ardelyx
AllUSDGBPEUR
Fund name | Fund size | $ARDX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.